Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vonoprazan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | VNN1 | O95497 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vonoprazan SCHEMBL29407860 | 1.00 | GAA (0.40) | GAAKMT2ACHRNB2CHRNB4CHRNA3 | |
| Vonoprazan SCHEMBL29419681 | 1.00 | GAA (0.40) | GAAKMT2ACHRNB2CHRNB4CHRNA3 | |
| Vonoprazan SCHEMBL29419683 | 1.00 | GAA (0.40) | GAAKMT2ACHRNB2CHRNB4CHRNA3 | |
| Vonoprazan SCHEMBL28725455 | 0.99 | GAA (0.39) | GAAKMT2ACHRNB2CHRNB4CHRNA3 | |
| Vonoprazan SCHEMBL29559657 | 0.99 | GAA (0.39) | GAAKMT2ACHRNB2CHRNB4CHRNA3 | |
| Vonoprazan SCHEMBL31647237 | 0.93 | CHRNB2 (0.39) | GAAKMT2ACHRNB2CHRNB4CHRNA3 | |
| Vonoprazan SCHEMBL194396 | 0.93 | CHRNB2 (0.39) | GAAKMT2ACHRNB2CHRNB4CHRNA3 | |
| Vonoprazan SCHEMBL29379818 | 0.93 | CHRNB2 (0.39) | GAAKMT2ACHRNB2CHRNB4CHRNA3 | |
| Vonoprazan SCHEMBL29407867 | 0.93 | CHRNB2 (0.39) | GAAKMT2ACHRNB2CHRNB4CHRNA3 | |
| Vonoprazan SCHEMBL194394 | 0.93 | CHRNB2 (0.39) | GAAKMT2ACHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 272 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025134080-A1 | PREPARATION OF HIGHLY PURE VONOPRAZAN FUMARATE SUBSTANTIALLY FREE OF IMPURITIES | SYMED LABS LIMITED (IN) | 2025-06-26 | — | — | WO | claimed |
| WO-2025023576-A1 | METHOD FOR PREPARING VONOPRAZAN FUMARATE | 한림제약(주) | 2025-01-30 | — | — | WO | claimed |
| CN-111527067-B | Process for the preparation of 1- [5- (2-fluorophenyl) -1- (pyridin-3-ylsulfonyl) -1H-pyrrol-3-yl ] -N-methylmethylamine monofumarate | 日本化学药品株式会社 | 2024-06-25 | — | — | CN | claimed |
| CN-118108703-A | Synthesis method of voronoi fumarate | 中山奕安泰医药科技有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-117069695-B | Potassium ion competitive acid retarder solid free form and preparation method thereof | 南京道尔医药研究院有限公司 | 2024-04-26 | — | — | CN | claimed |
| EP-3329921-B1 | TABLET | TAKEDA PHARMACEUTICALS CO (JP) | 2024-03-27 | — | — | EP | claimed |
| CN-117069695-A | Potassium ion competitive acid retarder solid free form and preparation method thereof | 南京道尔医药研究院有限公司 | 2023-11-17 | — | — | CN | claimed |
| CN-110590746-B | Preparation method of low-impurity Vonoprazan fumarate | 吉林汇康制药有限公司 | 2023-08-29 | — | — | CN | claimed |
| US-20230143246-A1 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-11 | — | — | US | claimed |
| CN-116082305-A | Preparation method and application of voronoi free base | 佛山奕安赛医药科技有限公司 | 2023-05-09 | — | — | CN | claimed |
| US-20110144161-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-16 | — | — | US | claimed |
| EP-2327692-A1 | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-06-01 | — | — | EP | claimed |
| US-20110124687-A1 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | claimed |
| EP-2309985-A2 | PHARMACEUTICAL COMPOSITION | Takeda Pharmaceutical Company Limited (JP) | 2011-04-20 | — | — | EP | claimed |
| EP-1919865-B1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2011-04-06 | — | — | EP | claimed |
| WO-2010013823-A2 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-04 | — | — | WO | claimed |
| US-20090275591-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2009-11-05 | — | — | US | claimed |
| US-20090143444-A1 | ACID SECRETION INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-04 | — | — | US | claimed |
| US-7498337-B2 | Acid secretion inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-03 | — | — | US | claimed |
| US-20070060623-A1 | antiulcer agents; proton pump inhibitors; side effect reduction; 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; superior acid secretion inhibitory effect; peptic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, or symptomatic gastroesophageal reflux disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143444-A1 | ACID SECRETION INHIBITOR | HRH2, VIP, CCKBR | GAA 57/4885KMT2A 4499/4885CHRNB2 3491/4885 |
| US-20110124687-A1 | PHARMACEUTICAL COMPOSITION | CYP2C19, MLST8, CYP3A43 | GAA 121/4885KMT2A 1862/4885CHRNB2 4514/4885 |
| US-20090275591-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITOR | HRH2, ASNS, GHSR | GAA 186/4885KMT2A 4151/4885CHRNB2 4265/4885 |
| US-20070060623-A1 | antiulcer agents; proton pump inhibitors; side effect reduction; 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; superior acid secretion inhibitory effect; peptic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, or symptomatic gastroesophageal reflux disease | HRH2, GIPR, HRH4 | GAA 1754/4885KMT2A 2631/4885CHRNB2 3452/4885 |
| US-20110144161-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | HRH2, GHSR, ASNS | GAA 180/4885KMT2A 4165/4885CHRNB2 4264/4885 |
| US-20230143246-A1 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | OTC, SLC38A7, SRI | GAA 1157/4885KMT2A 1070/4885CHRNB2 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.